Yimingang Ke: The first patient dosed in the phase I clinical trial of IMC-3/IMM72.

Yimingang announced that the first patient of the IMC-3/IMM72 phase I clinical trial has successfully been dosed. This marks a significant milestone in the company's IMC-3/IMM72 clinical research and lays a solid foundation for future clinical trials. IMC-3/IMM72 is a genetically modified next-generation activin receptor IIA-Fc fusion protein with higher activity and quality, and the company holds global intellectual property rights as well as development and commercialization rights.